News coverage about Epizyme (NASDAQ:EPZM) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Epizyme earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.247445783436 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s rankings:

EPZM has been the subject of a number of recent research reports. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a research report on Monday, November 6th. Royal Bank of Canada reaffirmed a “buy” rating and set a $20.00 price objective on shares of Epizyme in a research report on Friday, September 15th. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, October 16th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $22.67.

Epizyme (NASDAQ EPZM) traded up $0.65 during midday trading on Friday, reaching $14.25. The company had a trading volume of 335,200 shares, compared to its average volume of 587,004. Epizyme has a one year low of $9.30 and a one year high of $20.45.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. analysts anticipate that Epizyme will post -2.23 earnings per share for the current year.

In other Epizyme news, Director David M. Mott purchased 200,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were bought at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the acquisition, the director now owns 6,000 shares in the company, valued at $91,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the transaction, the insider now directly owns 23,123 shares in the company, valued at $380,142.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,000 shares of company stock worth $733,950. 25.20% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Epizyme (EPZM) Receives Daily Coverage Optimism Rating of 0.18” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/epizyme-epzm-receives-daily-coverage-optimism-rating-of-0-18/1696260.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.